Kynam-NO! says CHMP again to ISIS/Genzyme’s cardiovascular drug
This article was originally published in Scrip
Executive Summary
The EU’s CHMP has again refused to recommend approval for Genzyme Europe’s application to market the novel antisense agent Kynamro (mipomersen; licensed from ISIS Pharmaceuticals) for familial hypercholesterolaemia, on safety grounds.